MXPA04006059A - Preparacion liofilizada que contiene anticuerpos contra el receptor del factor de crecimiento epidermico. - Google Patents

Preparacion liofilizada que contiene anticuerpos contra el receptor del factor de crecimiento epidermico.

Info

Publication number
MXPA04006059A
MXPA04006059A MXPA04006059A MXPA04006059A MXPA04006059A MX PA04006059 A MXPA04006059 A MX PA04006059A MX PA04006059 A MXPA04006059 A MX PA04006059A MX PA04006059 A MXPA04006059 A MX PA04006059A MX PA04006059 A MXPA04006059 A MX PA04006059A
Authority
MX
Mexico
Prior art keywords
preparation containing
egf receptor
lyophilized preparation
containing antibodies
receptor
Prior art date
Application number
MXPA04006059A
Other languages
English (en)
Inventor
Kr Ger Ludwing
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MXPA04006059A publication Critical patent/MXPA04006059A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invencion se refiere a una preparacion farmaceutica liofilizada que contiene un anticuerpo contra el receptor del factor de crecimiento endotelial (receptor EGF). La preparacion presenta una mayor estabilidad al almacenamiento incluso a altas temperaturas y puede utilizarse en forma parenteral para el tratamiento de tumores luego de su reconstitucion.
MXPA04006059A 2001-12-21 2002-11-25 Preparacion liofilizada que contiene anticuerpos contra el receptor del factor de crecimiento epidermico. MXPA04006059A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10163459A DE10163459A1 (de) 2001-12-21 2001-12-21 Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor
PCT/EP2002/013223 WO2003053465A2 (de) 2001-12-21 2002-11-25 Lyophilisierte zubereitung enthaltend antikörper gegen den egf-rezeptor

Publications (1)

Publication Number Publication Date
MXPA04006059A true MXPA04006059A (es) 2004-09-27

Family

ID=7710502

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04006059A MXPA04006059A (es) 2001-12-21 2002-11-25 Preparacion liofilizada que contiene anticuerpos contra el receptor del factor de crecimiento epidermico.

Country Status (27)

Country Link
US (2) US20050220786A1 (es)
EP (1) EP1455824B1 (es)
JP (1) JP2005513110A (es)
KR (1) KR100942399B1 (es)
CN (1) CN100515495C (es)
AR (1) AR037971A1 (es)
AT (1) ATE403439T1 (es)
AU (1) AU2002358533B2 (es)
BR (1) BR0215266A (es)
CA (1) CA2470316A1 (es)
CO (1) CO5590939A2 (es)
DE (2) DE10163459A1 (es)
EC (1) ECSP045197A (es)
ES (1) ES2309220T3 (es)
HK (1) HK1071306A1 (es)
HU (1) HUP0402192A2 (es)
IL (1) IL162588A0 (es)
MX (1) MXPA04006059A (es)
MY (1) MY139055A (es)
NZ (1) NZ534211A (es)
PE (1) PE20030777A1 (es)
PL (1) PL205982B1 (es)
RU (1) RU2339402C2 (es)
TW (1) TWI318884B (es)
UA (1) UA83461C2 (es)
WO (1) WO2003053465A2 (es)
ZA (1) ZA200405785B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US20030224001A1 (en) * 1998-03-19 2003-12-04 Goldstein Neil I. Antibody and antibody fragments for inhibiting the growth of tumors
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
IL146480A0 (en) * 1999-05-14 2002-07-25 Imclone Systems Inc Treatment of refractory human tumors with epidermal growth factor receptor antagonists
AU2001295002B2 (en) * 2000-08-09 2007-05-31 Imclone Systems Incorporated Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
US20080008704A1 (en) * 2001-03-16 2008-01-10 Mark Rubin Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
DK1399484T3 (da) * 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
WO2004058821A2 (en) * 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
ATE328906T1 (de) * 2002-06-28 2006-06-15 Domantis Ltd Dual-specifische liganden mit erhöhter halbwertszeit
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
EP1622941A2 (en) * 2003-03-20 2006-02-08 ImClone Systems Incorporated Method of producing an antibody to epidermal growth factor receptor
DE10355251A1 (de) * 2003-11-26 2005-06-23 Merck Patent Gmbh Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
DE10355904A1 (de) 2003-11-29 2005-06-30 Merck Patent Gmbh Feste Formen von anti-EGFR-Antikörpern
RU2390353C2 (ru) * 2004-02-12 2010-05-27 Мерк Патент Гмбх Высококонцентрированные жидкие композиции анти-egfr антител
PL1735348T3 (pl) * 2004-03-19 2012-11-30 Imclone Llc Ludzkie przeciwciało przeciwko receptorowi naskórkowego czynnika wzrostu
JP2008519757A (ja) * 2004-11-12 2008-06-12 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 抗ｅｇｆｒ抗体の固形物
WO2007014073A2 (en) * 2005-07-22 2007-02-01 Amgen Inc. Concentrated protein lyophilates, methods, and uses
EA200801170A1 (ru) * 2005-12-01 2008-12-30 Домантис Лимитед Форматы неконкурентного доменного антитела, которые связываются с рецептором интерлейкина 1 первого типа
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
KR101378194B1 (ko) * 2005-12-20 2014-03-27 브리스톨-마이어스 스큅 컴퍼니 안정한 단백질 제제
KR20090021298A (ko) * 2006-06-14 2009-03-02 임클론 시스템즈 인코포레이티드 항-ｅｇｆｒ 항체의 동결건조 제제
WO2008029908A1 (fr) * 2006-09-07 2008-03-13 Kyowa Hakko Kirin Co., Ltd. Préparation pharmaceutique lyophilisée stable comprenant un anticorps
JP5631591B2 (ja) * 2006-10-06 2014-11-26 アムジエン・インコーポレーテツド 安定な抗体製剤
EP2094247B1 (en) * 2006-10-20 2022-06-29 Amgen Inc. Stable polypeptide formulations
CN101679511A (zh) 2007-06-06 2010-03-24 杜门蒂斯有限公司 多肽、抗体可变域和拮抗剂
CN101716343A (zh) * 2008-10-09 2010-06-02 哈药集团生物工程有限公司 一种单克隆抗体的冻干制剂
SI2672994T1 (sl) 2011-02-11 2018-09-28 Merck Patent Gmbh Protitelo proti alfa-v integrinu za zdravljenje raka prostate
KR102031020B1 (ko) * 2011-03-31 2019-10-14 머크 샤프 앤드 돔 코포레이션 인간 프로그램화된 사멸 수용체 pd-1에 대한 항체의 안정한 제제 및 관련된 치료
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
IN2014CN03555A (es) 2011-10-25 2015-07-03 Onclave Therapeutics Ltd
US20190060241A1 (en) * 2016-04-13 2019-02-28 Medimmune, Llc Use of amino acids as stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents
BR112019013202A2 (pt) 2016-12-28 2019-12-10 Japan Chem Res formulação liofilizada
KR20210028165A (ko) * 2018-06-01 2021-03-11 라쿠텐 메디칼, 인크. 프탈로시아닌 염료 접합체 조성물
EP3867276A1 (en) 2018-10-19 2021-08-25 Merck Patent GmbH Abituzumab for the treatment of colorectal cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4242863A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
NZ517150A (en) * 1999-08-27 2005-01-28 Genentech Inc Dosages for treatment with anti-ErbB2 antibodies

Also Published As

Publication number Publication date
AU2002358533A1 (en) 2003-07-09
HUP0402192A2 (hu) 2005-01-28
CN1606455A (zh) 2005-04-13
UA83461C2 (uk) 2008-07-25
DE50212615D1 (de) 2008-09-18
TWI318884B (en) 2010-01-01
RU2339402C2 (ru) 2008-11-27
CA2470316A1 (en) 2003-07-03
ZA200405785B (en) 2005-06-29
AR037971A1 (es) 2004-12-22
ECSP045197A (es) 2004-08-27
PL369848A1 (en) 2005-05-02
PE20030777A1 (es) 2003-09-11
IL162588A0 (en) 2005-11-20
EP1455824B1 (de) 2008-08-06
US20080166346A1 (en) 2008-07-10
EP1455824A2 (de) 2004-09-15
KR20040074099A (ko) 2004-08-21
TW200306205A (en) 2003-11-16
HK1071306A1 (en) 2005-07-15
CO5590939A2 (es) 2005-12-30
AU2002358533B2 (en) 2009-01-15
WO2003053465A3 (de) 2003-12-04
MY139055A (en) 2009-08-28
NZ534211A (en) 2006-01-27
DE10163459A1 (de) 2003-07-03
JP2005513110A (ja) 2005-05-12
PL205982B1 (pl) 2010-06-30
ATE403439T1 (de) 2008-08-15
US20050220786A1 (en) 2005-10-06
CN100515495C (zh) 2009-07-22
ES2309220T3 (es) 2008-12-16
KR100942399B1 (ko) 2010-02-17
BR0215266A (pt) 2004-12-07
RU2004122632A (ru) 2005-05-20
WO2003053465A2 (de) 2003-07-03

Similar Documents

Publication Publication Date Title
MXPA04006059A (es) Preparacion liofilizada que contiene anticuerpos contra el receptor del factor de crecimiento epidermico.
MY137181A (en) Pulmonary administration of chemically modified insulin
RS20110024A (en) ANTIBODIES THAT BLOCK CRIPTO AND USE IT
TWI263640B (en) Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
ZA975851B (en) Hepatocyte grown factor receptor agonists and uses thereof
WO2002072636A3 (en) Crystals of whole antibodies and fragments thereof and methods for making and using them
IL185142A0 (en) Lentiviral packaging constructs
UA85993C2 (ru) Конъюгат, который содержит бактериальный суперантиген и антительную составную, фармацевтическая композиция, которая его содержит, и способ лечения рака у млекопитающего
AU2002359727A1 (en) Fused cyclic modulators of nuclear hormone receptor function
TR200001946T2 (tr) Aşı
EP1553975A4 (en) OPTIMIZED FC VARIANTS AND MANUFACTURING METHOD THEREFOR
PL361707A1 (en) Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
BR0212740B1 (pt) material pulverizado e material cerÂmico fabricado a partir do mesmo.
MXPA04000340A (es) FORMULACION LIQUIDA QUE COMPRENDE CETUXIMAB Y eSTER DE aCIDO GRASO DE POLIOXIETILEN SORBITaN.
DE60003943D1 (de) Trimegestone enthaltende pharmazeutische zusammensetzungen
MY124078A (en) Eletriptan hydrobromide monohydrate
IL156799A0 (en) Peptides having affinity for the gp120 viral protein and use thereof
NO993407L (no) Fremstilling av proteinpreparater med nedsatt aggregatinnhold
MXPA03007992A (es) Composicion farmaceutica de fragmentos f(ab)2 de anticuerpos y un proceso para su preparacion
DE69943239D1 (de) Verbindungen mit wachstumshormon-freisetzenden eigenschaften
WO2002024181A3 (en) The use of melatonin for induction of general anesthesia
MXPA04002103A (es) Una proteina de union a caspasa-8, su preparacion y uso.
IL156640A (en) Process for preparing arylethanoldiamines from imidazooxazoles, starting material and intermediate used in the process
PL1664087T3 (pl) Izolacja prionów z zastosowaniem cząstek tlenków metali
PL366565A1 (en) Fused cyclic modulators of nuclear hormone receptor function

Legal Events

Date Code Title Description
FG Grant or registration